Reported Earlier: Personalis Reports Preliminary Q4 Revenue Of $17M-$18M; FY25 Revenue Of $69M-$70M

• Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests; full year volume of 16,233 tests outperforms initial 2025 projections
• Strong cash position of approximately $240 million provides capital for commercial expansion
• Secured pivotal Medicare coverage for breast cancer surveillance, validating ultrasensitive MRD technology
• Preliminary Q4 revenue of $17 to $18 million; preliminary full year revenue of $69 to $70 million

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025.

Fourth Quarter Strategic and Operational Highlights

• Secured Milestone Medicare Coverage: Received Medicare coverage approval for the surveillance of cancer recurrence in breast cancer patients, a key catalyst for clinical revenue and market share growth in the MRD space.
• Published Landmark TRACERx Data: Announced the publication of one of the largest and most comprehensive non-small cell lung cancer (NSCLC) patient cohorts to date in the journal Cell, demonstrating the clinical importance of Personalis' ultrasensitive MRD approach.
• Validation of ctDNA Dynamics: Published VHIO data in Clinical Cancer Research titled "Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy," further reinforcing the clinical validity the NeXT Personal platform in a broad array of cancer types.

Preliminary Full Year 2025 Financial Results

• Total Revenue: Expected to be in the range of $69.0 to $70.0 million compared with $84.6 million for 2024.
• Clinical Momentum: Clinical test revenue reached approximately $2.0 million, more than doubling the $0.8 million reported in 2024.
• Volume Outperformance: Clinical test volume reached approximately 16,233 tests, a nearly 400% increase over the 3,285 tests delivered in 2024. This performance exceeded the company's internal growth targets by more than 20% and signals a significant shift in market adoption for ultrasensitive MRD testing.
• Core Revenue Streams: Pharma tests, services, and all other customers contributed approximately $49.0 million to $50.0 million. Revenue from enterprise sales (Natera) and population sequencing (the U.S. Department of Veterans Affairs Million Veterans Program (VA MVP)) totaled approximately $18.0 million.

Preliminary Fourth Quarter 2025 Financial Results

• Quarterly Revenue: Expected to be in the range of $17.0 million to $18.0 million.
• Accelerating Volume: Delivered 6,183 clinical tests in the fourth quarter, representing a 41% sequential increase over the third quarter of 2025.
• Clinical Revenue: Preliminary clinical test revenue of approximately $0.9 million, compared with $0.2 million in the prior year period.
• Core Revenue Streams: Pharma tests, services, and all other customers contributed approximately $11.6 million to $12.6 million. Revenue from enterprise sales (Natera) and population sequencing (the VA MVP) totaled approximately $4.5 million.
• Strong Liquidity: Ended the year with approximately $240.0 million in cash, cash equivalents, and short-term investments. This includes approximately $109.0 million in net proceeds from the company's At-The-Market (ATM) sales program, executed at a weighted-average price of $8.43 per share.